Physician profile
Mohammad A Saeed
NPI 1861515074
$9,087.87
in general payments reported to CMS, 2019-2025
34 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 90% of Psychosomatic Medicine providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $795 · 2021: $1,408 · 2022: $1,223 · 2023: $1,592 · 2024: $1,628 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,312.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,859.69 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,599.99 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $655.99 | 2021-2025 | Qelbree |
| Corium, LLC | $560.05 | 2021-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $494.55 | 2019-2024 | Rexulti, Abilify Mycite, Abilify Maintena |
| Indivior INC. | $463.54 | 2019-2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $398.65 | 2019-2023 | Jornay Pm |
| Lundbeck LLC | $376.17 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $375.68 | 2019-2021 | |
| Abbvie INC. | $227.56 | 2022-2025 | |
| Allergan, INC. | $226.91 | 2019-2020 | |
| Alkermes, INC. | $204.29 | 2019-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $186.16 | 2020-2022 | |
| Axsome Therapeutics, INC. | $180.33 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $167.96 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $136.23 | 2019-2021 | |
| Biosense Webster, INC. | $135.49 | 2019 | |
| Neos Therapeutics, Lp | $107.81 | 2019-2025 | Adzenys Xr-Odt |
| Nevro Corp. | $99.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $88.64 | 2025 | Cobenfy |
| Bausch Health US, LLC | $72.02 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $69.81 | 2020-2022 | |
| Orexo US, INC. | $57.35 | 2019-2021 | |
| Neuronetics, INC. | $46.48 | 2019-2022 | |
| Noven Therapeutics, LLC | $42.25 | 2020-2021 | |
| Tris Pharma INC | $38.88 | 2024-2025 | Dyanavel Xr |
| Shire North American Group INC | $37.87 | 2019 | |
| Almatica Pharma LLC | $32.34 | 2023-2025 | Loreev Xr |
| Mdd US Operations, LLC | $31.43 | 2020 | |
| Impulse Dynamics (USA) INC. | $29.26 | 2023 | Optimizer |
| Biogen, INC. | $29.08 | 2025 | Zurzuvae |
| Tempus Ai, INC | $27.37 | 2024 | Tempus Pixel |
| Idorsia Pharmaceuticals US INC | $14.87 | 2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $14.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.